<?xml version="1.0"?>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Single-cell RNAseq profiling of human gamma delta T lymphocytes in virus-related cancers and COVID-19 disease</dc:title>
  <dc:creator>Cerapio, J. P.</dc:creator>
  <dc:creator>Perrier, M.</dc:creator>
  <dc:creator>Pont, F.</dc:creator>
  <dc:creator>Tosolini, M.</dc:creator>
  <dc:creator>Laurent, C.</dc:creator>
  <dc:creator>/Bertani, St&#xE9;phane</dc:creator>
  <dc:creator>Fournie, J. J.</dc:creator>
  <dc:subject>human</dc:subject>
  <dc:subject>gammadelta</dc:subject>
  <dc:subject>lymphocyte</dc:subject>
  <dc:subject>tumor</dc:subject>
  <dc:subject>COVID-19</dc:subject>
  <dc:subject>transcriptome</dc:subject>
  <dc:subject>single cell</dc:subject>
  <dc:subject>differentiation</dc:subject>
  <dc:subject>trajectory</dc:subject>
  <dc:description>The detailed characterization of human gamma delta T lymphocyte differentiation at the single-cell transcriptomic (scRNAseq) level in tumors and patients with coronavirus disease 2019 (COVID-19) requires both a reference differentiation trajectory of gamma delta T cells and a robust mapping method for additional gamma delta T lymphocytes. Here, we incepted such a method to characterize thousands of gamma delta T lymphocytes from (n = 95) patients with cancer or adult and pediatric COVID-19 disease. We found that cancer patients with human papillomavirus-positive head and neck squamous cell carcinoma and Epstein-Barr virus-positive Hodgkin's lymphoma have gamma delta tumor-infiltrating T lymphocytes that are more prone to recirculate from the tumor and avoid exhaustion. In COVID-19, both TCRV gamma 9 and TCRV gamma non9 subsets of gamma delta T lymphocytes relocalize from peripheral blood mononuclear cells (PBMC) to the infected lung tissue, where their advanced differentiation, tissue residency, and exhaustion reflect T cell activation. Although severe COVID-19 disease increases both recruitment and exhaustion of gamma delta T lymphocytes in infected lung lesions but not blood, the anti-IL6R therapy with Tocilizumab promotes gamma delta T lymphocyte differentiation in patients with COVID-19. PBMC from pediatric patients with acute COVID-19 disease display similar gamma delta T cell lymphopenia to that seen in adult patients. However, blood gamma delta T cells from children with the COVID-19-related multisystem inflammatory syndrome are not lymphodepleted, but they are differentiated as in healthy PBMC. These findings suggest that some virus-induced memory gamma delta T lymphocytes durably persist in the blood of adults and could subsequently infiltrate and recirculate in tumors.</dc:description>
  <dc:date>2021</dc:date>
  <dc:type>text</dc:type>
  <dc:identifier>https://www.documentation.ird.fr/hor/fdi:010083797</dc:identifier>
  <dc:identifier>fdi:010083797</dc:identifier>
  <dc:identifier>Cerapio J. P., Perrier M., Pont F., Tosolini M., Laurent C., Bertani St&#xE9;phane, Fournie J. J.. Single-cell RNAseq profiling of human gamma delta T lymphocytes in virus-related cancers and COVID-19 disease. 2021, 13 (11),  2212 [14 p.]</dc:identifier>
  <dc:language>EN</dc:language>
</oai_dc:dc>
